Skip to main content

Horstmeier Paul's Form 4/A amendment

Amended

Health Catalyst, Inc. (HCAT) · filed Dec 29, 2021

Accession no.
0001562180-21-007901
Filed
Dec 29, 2021
Trade date
Dec 7, 2021
Filing delay
22 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Dec 9, 2021

This filing lists 2 non-derivative transactions. Open-market sales total $99.5K. It was filed 22 days after the trade.

This amendment replaces 0001562180-21-007617 (filed Dec 9, 2021).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Horstmeier PaulCIK 0001780978Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 7, 2021Common StockSSaleDisposed−2,082$39.97F2−$83,217.5497,098Direct
Dec 7, 2021Common StockSSaleDisposed−400$40.61F3−$16,24496,698Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.

F2

Represents the weighted average sale price of the shares sold ranging from $39.46 to $40.42 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price of the shares sold ranging from $40.58 to $40.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)